TScan Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 48.73 | -100% | -2.79 | -100% |
| P/S |
|
18.54 | 33.76 | -45.07% |
|
|
| P/BV |
|
2.59 | 4.83 | -46.38% |
|
|
| P/FCF |
|
-1.64 | 61 | -102.69% |
|
|
| Ev/Ebitda |
|
-3.97 | -22.19 | -82.13% |
|
|
| Ev/S |
|
16.6 | 22.57 | -26.45% |
|
|
| Ev/FCF |
|
-5.42 | 68.74 | -107.88% |
|
|
| E/P |
|
-0.8417 | 0.0178 | -4835.65% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-418.53 | 4.98 | -8509.44% | -893.6 | -53.16% |
| ROE |
|
-59.14 | 9.61 | -715.27% |
|
|
| ROA |
|
-32.78 | 0.3443 | -9622.69% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
-423.86 | -25.17 | 1583.98% |
|
|
| ROCE |
|
-61.95 | 15.45 | -500.97% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.3779 | -3.68 | -89.72% | -0.6957 | -45.68% |
| Nеt Debt/Ebitda |
|
0.4646 | -3.44 | -113.52% |
|
|
| Debt/Ratio |
|
0.1223 | 0.1986 | -38.4% |
|
|
| Debt/Equity |
|
3.3 | 1.56 | 111.7% |
|
|
| Debt/Net Income |
|
-0.3732 | 10.32 | -103.61% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5411 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2256 | -100% |
|
|
| Average dividend growth |
|
0 | 1.07 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.498 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5411 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
1813.55 | -57.64 | -3246.34% | ||
| Growth impulse Ebitda in 5 years |
|
484.66 | -90.94 | -632.94% | ||
| Growth impulse Net Income in 5 years |
|
581.05 | -97.8 | -694.12% | ||
| Growth impulse FCF in 5 years |
|
367.42 | -49.48 | -842.56% | ||
| Growth impulse EPS in 5 years |
|
148.41 | -32.41 | -557.91% |
IP Score
4.59/10
